Referensi
BROGDEN, Rex N.; FAULDS, Diana. Goserelin: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in prostate cancer. Drugs & Aging, 1995, 6: 324-343.
RAJA, T., et al. Gonadotropin-releasing hormone agonists in prostate cancer: A comparative review of efficacy and safety. Indian Journal of Cancer, 2022, 59.Suppl 1: S142-S159.
MODI, Dimple, et al. Long acting injectables for the treatment of prostate cancer. Journal of Drug Delivery Science and Technology, 2024, 105996.
ABUFARAJ, Mohammad, et al. Differential impact of gonadotropin-releasing hormone antagonist versus agonist on clinical safety and oncologic outcomes on patients with metastatic prostate cancer: a meta-analysis of randomized controlled trials. European Urology, 2021, 79.1: 44-53.
GU, Li; LI, Xurui; LIU, Wentao. Adverse cardiovascular effect following gonadotropin-releasing hormone antagonist versus GnRH agonist for prostate cancer treatment: A systematic review and meta-analysis. Frontiers in Endocrinology, 2023, 14: 1157857.
